Provided by Tiger Fintech (Singapore) Pte. Ltd.

CALIDI BIOTHERAPEUTICS INC

0.5936
-0.0223-3.62%
Post-market: 0.5501-0.0435-7.33%19:58 EDT
Volume:2.57M
Turnover:1.53M
Market Cap:20.49M
PE:-0.20
High:0.6432
Open:0.6029
Low:0.5695
Close:0.6159
Loading ...

Company Profile

Company Name:
CALIDI BIOTHERAPEUTICS INC
Exchange:
AMEX
Establishment Date:
2014
Employees:
28
Office Location:
4475 Executive Drive,Suite 200,San Diego,California,United States
Zip Code:
92121
Fax:
858 794 9605
Introduction:
Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors. The company offers NeuroNova platform and SuperNova platform. The company is headquartered in San Diego, California.

Directors

Name
Position
Eric Poma
Chief Executive Officer and Director
James Schoeneck
Chairman of the Board and Director
Alan Stewart
Director
Allan Camaisa
Director
George Peoples
Director
Scott Leftwich
Director

Shareholders

Name
Position
Eric Poma
Chief Executive Officer and Director
Andrew Jackson
Chief Financial Officer
Boris Minev
President of Medical and Scientific Affairs
Wendy Pizarro Campbell
Chief Corporate Development Officer, Chief Legal Officer, Chief Diversity Officer and Corporate Secretary